Kernekoncepter
CAR T-cell therapies show promising results in mantle cell lymphoma treatment.
Statistik
"In the original data published in The New England Journal of Medicine, the overall response rate was 93% and the complete response (CR) was 67%."
"After two more years of follow-up, we reported at the American Society of Clinical Oncology last year in 2022 at 3 years of follow up that the overall response rate was 91%."
"The response rate was 83%, the CR was 73%, and the CRS was 15% at grade 3 or 4."
Citater
"Life is like this — eventually you find your niche, and you will not let it go because it is the best way to contribute, pay back society, and pay back what people invest into you." - Dr. Michael Wang
"I would be very careful giving the patient CAR T cells. I usually have a family conference to tell them the risks and what will happen — 20% of patients go to ICU, 3% or 4% or 5% get intubation, and 2% of people don't survive." - Dr. Michael Wang